Current status of a helicopter transportation system on remote islands for patients undergoing mechanical thrombectomy.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 07 09 2020
accepted: 21 12 2020
entrez: 19 1 2021
pubmed: 20 1 2021
medline: 11 5 2021
Statut: epublish

Résumé

Mechanical thrombectomy (MT) is standard treatment for acute ischemic stroke (AIS) with large-vessel occlusion within 6 h of symptom onset to treatment initiation (OTP). Recent trials have extended the therapeutic time window for MT to within 24 h. However, MT treatment remains low in remote areas. Nagasaki Prefecture, Japan has many inhabited islands with no neurointerventionalists. Our hospital on the mainland is a regional hub for eight island hospitals. We evaluated clinical outcomes of MT for patients with AIS on these islands versus on the mainland. During 2014-2019, we reviewed consecutive patients with AIS who received MT at our hospital. Patients comprised the Islands group and Mainland group. Patient characteristics and clinical outcomes were compared between groups. We included 91 patients (Islands group: 15 patients, Mainland group: 76 patients). Seven patients (46.7%) in the Islands group versus 43 (56.6%) in the Mainland group achieved favorable outcomes. Successful recanalization was obtained in 11 patients (73.3%) on the islands and 67 (88.2%) on the mainland. The median OTP time in the Islands was 365 min. In both the Islands and Mainland groups, the OTP time and successful recanalization were associated with functional outcome. The modified Rankin Scale (mRS) score at 90 days ≤2 was obtained in two patients and mRS = 3 in four patients among eight patients with OTP time >6 h. Few patients with AIS on remote islands have received MT. Although patients who underwent MT on the islands had longer OTP, the clinical outcomes were acceptable. OTP time on remote islands must be shortened, as this is related to functional outcome. In some cases with successful recanalization, a favorable outcome can still be obtained even after 6 h. Even if OTP exceeds 6 h, it is desirable to appropriately select patients and actively perform MT.

Sections du résumé

BACKGROUND
Mechanical thrombectomy (MT) is standard treatment for acute ischemic stroke (AIS) with large-vessel occlusion within 6 h of symptom onset to treatment initiation (OTP). Recent trials have extended the therapeutic time window for MT to within 24 h. However, MT treatment remains low in remote areas. Nagasaki Prefecture, Japan has many inhabited islands with no neurointerventionalists. Our hospital on the mainland is a regional hub for eight island hospitals. We evaluated clinical outcomes of MT for patients with AIS on these islands versus on the mainland.
METHODS
During 2014-2019, we reviewed consecutive patients with AIS who received MT at our hospital. Patients comprised the Islands group and Mainland group. Patient characteristics and clinical outcomes were compared between groups.
RESULTS
We included 91 patients (Islands group: 15 patients, Mainland group: 76 patients). Seven patients (46.7%) in the Islands group versus 43 (56.6%) in the Mainland group achieved favorable outcomes. Successful recanalization was obtained in 11 patients (73.3%) on the islands and 67 (88.2%) on the mainland. The median OTP time in the Islands was 365 min. In both the Islands and Mainland groups, the OTP time and successful recanalization were associated with functional outcome. The modified Rankin Scale (mRS) score at 90 days ≤2 was obtained in two patients and mRS = 3 in four patients among eight patients with OTP time >6 h.
CONCLUSIONS
Few patients with AIS on remote islands have received MT. Although patients who underwent MT on the islands had longer OTP, the clinical outcomes were acceptable. OTP time on remote islands must be shortened, as this is related to functional outcome. In some cases with successful recanalization, a favorable outcome can still be obtained even after 6 h. Even if OTP exceeds 6 h, it is desirable to appropriately select patients and actively perform MT.

Identifiants

pubmed: 33465116
doi: 10.1371/journal.pone.0245082
pii: PONE-D-20-28196
pmc: PMC7815141
doi:

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0245082

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2016 Mar 03;11(3):e0150668
pubmed: 26938774
N Engl J Med. 2015 Jan 1;372(1):11-20
pubmed: 25517348
No Shinkei Geka. 2020 Sep;48(9):781-792
pubmed: 32938806
Neurol Med Chir (Tokyo). 2019 Dec 15;59(12):504-510
pubmed: 31748441
Cerebrovasc Dis. 2020;49(3):292-300
pubmed: 32544919
JAMA Neurol. 2017 May 1;74(5):549-556
pubmed: 28319240
Stroke. 2015 Mar;46(3):732-9
pubmed: 25672784
N Engl J Med. 2018 Jan 4;378(1):11-21
pubmed: 29129157
Neurosurg Focus. 2017 Apr;42(4):E8
pubmed: 28366070
Ann Neurol. 2015 Oct;78(4):584-93
pubmed: 26153450
Stroke. 2017 Jul;48(7):1976-1979
pubmed: 28512170
Lancet. 2016 Apr 23;387(10029):1723-31
pubmed: 26898852
Stroke. 2013 Sep;44(9):2650-63
pubmed: 23920012
Neurology. 2019 Nov 26;93(22):e1997-e2006
pubmed: 31649112
Stroke. 2019 Dec;50(12):e344-e418
pubmed: 31662037
J Am Heart Assoc. 2019 Aug 20;8(16):e013306
pubmed: 31390925
JAMA. 1995 Oct 4;274(13):1017-25
pubmed: 7563451
N Engl J Med. 2018 Feb 22;378(8):708-718
pubmed: 29364767
J Neurol. 2020 Jul 15;:
pubmed: 32671526
Circulation. 2017 Dec 12;136(24):2311-2321
pubmed: 28943516
JAMA. 2016 Sep 27;316(12):1279-88
pubmed: 27673305
J Am Heart Assoc. 2019 Jul 2;8(13):e012743
pubmed: 31257969
JAMA. 2019 Jul 16;322(3):252-263
pubmed: 31310296
EClinicalMedicine. 2019 Sep 03;14:53-58
pubmed: 31709402
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
World Neurosurg. 2020 Jun;138:e839-e846
pubmed: 32229302

Auteurs

Takeshi Hiu (T)

Department of Neurosurgery, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.
Department of Neurosurgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Shimpei Morimoto (S)

Innovation Platform & Office for Precision Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.
Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan.

Ayaka Matsuo (A)

Department of Neurosurgery, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.

Kei Satoh (K)

Department of Neurosurgery, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.

Hiroaki Otsuka (H)

Department of Neurology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.

Fumiya Kutsuna (F)

Department of Neurology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.

Keisuke Ozono (K)

Department of Neurosurgery, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.

Kosuke Hirayama (K)

Department of Neurosurgery, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.

Chikaaki Nakamichi (C)

Department of Emergency, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.

Kazumi Yamasaki (K)

Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.

Yuka Ogawa (Y)

Department of Neurosurgery, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.

Eri Shiozaki (E)

Department of Neurosurgery, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.

Yoichi Morofuji (Y)

Department of Neurosurgery, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.

Ichiro Kawahara (I)

Department of Neurosurgery, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.

Nobutaka Horie (N)

Department of Neurosurgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Yohei Tateishi (Y)

Department of Neurology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Tomonori Ono (T)

Department of Neurosurgery, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.

Wataru Haraguchi (W)

Department of Neurosurgery, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.

Tsuyoshi Izumo (T)

Department of Neurosurgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Akira Tsujino (A)

Department of Neurology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Takayuki Matsuo (T)

Department of Neurosurgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Keisuke Tsutsumi (K)

Department of Neurosurgery, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH